Plasmacytoid dendritic cell tumor: A case report by Füruzan Kacar Döger et al.
312 Case Report  
Plasmacytoid dendritic cell tumor:  
A case report
Plasmasitoid dendritik hücreli tumor: Bir olgu sunumu
Füruzan Kacar Döger1, Emel Dikicioğlu Çetin1, Mine Hekimgil2, 
Meltem Özdoğan Uslu3, Gürhan Kadıköylü4, Nazan Özsan2, Ekin Şavk3, Zahit Bolaman4
1Department of Pathology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
2Department of Pathology, Faculty of Medicine, Ege University, İzmir, Turkey
3Department of Dermatology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
4Deptartment of Hematology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
Address for Correspondence: Assoc. Prof. Füruzan Kacar Döger, Department of Pathology, Faculty of Medicine, Adnan Menderes University, 
00910 Aydın, Turkey Phone: +90 532 795 80 66 E-mail: fdoger@adu.edu.tr
doi:10.5152/tjh.2011.87
Abstract
A 62-year-old man presented with a painless eruption on his arms and trunk. Physical examination 
showed 2 well-demarcated erythematous plaques on the anterior trunk and 6 purple-red papules on 
the back and upper extremities. Blood chemistry and computed tomography results were normal. 
Herein we describe a patient with plasmacytoid dendritic cell neoplasm in the absence of systemic 
symptoms.  (Turk J Hematol 2011; 28: 312-6)
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Özet
Altmış iki yaşında erkek hasta gövdesinde ve kollarındaki ağrısız erupsiyon şikayetleri ile başvurdu. 
Fizik muyane de gövdesinin ön kısmında iyi sınırlı eritamatous plak, üst ekstremite ve sırtında mor 
kırmızı papuller saptandı. Kan biyokimyası ve tomografisi olağandı. Burada, sistemik bulgusu olmayan 
plasmasitoid dendritik hücreli neoplasmı olan bir hastayı sunduk (Turk J Hematol 2011; 28: 312-6)
Anahtar kelimeler: Kutanöz lenfoma, NK hücreli lenfoma, hematodermik lenfoma, plasmasitoid 
dendritik hücreli neoplazi
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According to the WHO 2008 classification of lym-
phoid  malignancies,  plasmacytoid  dendritic  cell 
tumor-a rare non-Hodgkin’s lymphoma (NHL)-was 
formerly defined as blastic NK-cell lymphoma in the 
WHO 2001 classification and as CD4+/CD56+ hema-
todermic neoplasm in the European Organization of 
Research and Treatment of Cancer 2005 classifica-
tion  of  cutaneous  lymphoma  [1-10].  Plasmacytoid 
dendritic cell tumors generally occur in middle-aged 
and elderly men; the skin is usually the first site of 
presentation  in  90%  of  patients  [1,4].  Additionally, 
there is a high incidence of lymph node and bone 
marrow involvement [1,9,11,12]. The tumor is char-
acterized  by  a  monotonous  infiltrate  of  medium-
sized cells with fine chromatin, resembling a lym-
phoblast. The overlying epidermis is not affected and 
there  is  a  well-preserved  grenz  zone.  Prognosis  is 
poor and overall survival is <2 years [11-14].
Case Report
A 62-year-old male presented to Adnan Menderes 
University  Hospital,  Department  of  Dermatology 
with painless eruptions on his arms and trunk that 
began 5 months earlier (Figure 1). Physical exami-
nation  showed  2  well-demarcated  erythematous 
plaques  (4×10  cm  and  4×5  cm)  on  the  anterior 
trunk of the body, and 6 purple-red papules (0.3-0.5-
cm) on the back and upper extremities. Palpation of 
the liver and spleen was normal. The right axillary 
lymph node measured 4×3 cm. Written informed 
consent was obtained from the patient.
The patient’s hematological parameters were as 
follows: Hb: 13.1 g/dL; Hct: 40%; RBC count: 4.45×106 
mm3; WBC count: 9.9×103 mm3; Plt count: 289×103 
mm3.  The  erythrocyte  sedimentation  rate  and 
C-reactive protein were 48 mm/h and 11 mg/L (nor-
mal range: 0-6 mg/L), respectively. Peripheral blood 
smear, biochemical parameters, and bone marrow 
aspiration  and  biopsy  were  normal.  Computed 
tomography of the cervix, thorax, abdomen, pelvis, 
and nasal cavity were normal, with the exception of 
the right axillary lymph node. 
A  punch  biopsy  was  performed  for  definitive 
diagnosis.  Histopathological  examination  of  the 
biopsy specimen showed tumor infiltration in the 
dermis.  The  infiltrate  was  monotonous,  involving 
the  dermis  and  sometimes  the  subcutaneous  tis-
sue, and was composed of atypical medium-sized 
mononuclear cells with finely dispersed chromatin. 
The tumor consisted of medium-large blastoid-like 
cells. The epidermis was intact with a grenz zone 
(Figure 2). There are many mitotic figures. On the 
other hand, signs associated with a poor prognosis, 
such  as  necrosis  and/or  angioinvasion,  were  not 
observed; nor were inflammatory cells. 
Figure 1a-b. Erythematous Nodules on the Patient’s Chest (a) and Multiple Papules and Nodules on His Back and Arms (b) at Presentation
a b
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CD4, and CD123, but did not stain with myeloper-
oxidase (MPO), TdT, CD34, CD20, CD3, CD5, CD 79, 
CD30, Cyclin D1, chromogranin, S100, or EBER. On 
the basis of the histopathologic findings, the patient 
was diagnosed as plasmacytoid dendritic cell neo-
plasm.  The  patient  was  stage  IA-E,  based  on  the 
Ann-Arbor  staging  system.  CHOP  (cyclophospha-
mide,  adriamycin,  vincristine,  and  prednisone) 
combination  chemotherapy  was  administered  as 
four 21-d courses [14]. After the first chemotherapy 
course  the  skin  lesions  regressed  and  lymphade-
nopathy  disappeared  (Figure  4a  and  b). During  2 
years of follow-up skin lesions and bone marrow 
involvement did not recur. 
Discussion
Plasmacytoid dendritic cell tumors typical present 
with widespread purplish dermal nodules or tumors. 
These lesions are usually located on the trunk; how-
ever, the extremities, head, and neck can be involved. 
Most patients also have extracutaneous manifesta-
tions  at  presentation  [1,4,5,10].  Plasmacytoid  den-
dritic cell tumors were formerly categorized as blas-
tic NK-cell lymphoma because of CD56 expression 
[1-3,6,7,11,13]. Moreover, CD4 expression is positive, 
but CD2, CD3, and CD7 expression is usually nega-
tive. While CD68 is negative or slightly positive, TdT 
and CD34 may be positive in some cases, but evi-
dence of T-cell receptor (TCR) gene rearrangement 
Figure 3. Tumor Cells with Strong Positive CD56 Staining (CD56, 200×) Figure 2. Intact Epidermis with A Grenz Zone (H&E, 200×)
Figure 4 a-b. Regression of the Patient’s Lesions Following Chemotherapy
a b
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the  nasal  cavity,  skin  tumors  accompanied  by 
enlargement of lymph nodes are frequently observed. 
No correlation with the Epstein-Barr virus has been 
reported. 
Between 1994 and 2007 there were 121 report-
ed cases of plasmacytoid dendritic cell neoplasm). 
The  presented  patient  had  painless  cutaneous 
eruptions  and  lymphadenopathy.  Skin  biopsy  of 
these lesions showed neoplastic infiltration of the 
dermis with a grenz zone. Additionally, there was a 
high  mitotic  rate.  Neoplastic  cells  were  atypical 
and had a blastic appearance. Histologically, the 
lymphomas  showed  no  significant  epidermotro-
pism.  Immunohistochemical  staining  was  very 
typical for plasmacytoid dendritic cell neoplasm. 
Although  the  blastic  cytological  appearance  and 
CD56  expression  initially  suggested  that  NK-cells 
were  the  origin  of  this  type  of  lymphoma,  more 
recent  studies  reported  that  the  cells  express 
CD123 and TCL1, suggesting a plasmacytoid den-
dritic cell origin [2,6,7,9-11].
Currently, although no characteristic cutaneous 
manifestations are known and no consensus on the 
treatment  of  plasmacytoid  dendritic  cell  tumors 
exists, aggressive chemotherapy regimens are rec-
ommended. Anthracycline-based chemotherapies, 
such as the CHOP and hyper-CVAD regimens, may 
be effective, whereas high-dose chemotherapy and 
autologous stem cell transplantation may be appro-
priate  in  some  selected  cases  [3,5,8-11,13].  The 
presented patient received the CHOP chemothera-
py regimen, and after the first course the patient’s 
skin lesions regressed and lymphadenopathy disap-
peared. During 2 years of follow- skin lesions and 
bone marrow involvement did not recur. 
In conclusion, plasmacytoid dendritic cell tumors 
are a rare form of cutaneous malignant lymphoma. 
This neoplasm has an aggressive course and rapid 
development of disseminated disease in the major-
ity  of  patients.  Definitive  pathological  diagnosis  is 
essential for proper treatment and a good progno-
sis. Future research should focus on the character-
ization of this lymphoma and the establishment of 
effective treatment modalities.
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